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Abstract
Whenever new substances are proposed for use as sources of nutrients in food supplements, foods for
the general population or foods for speciﬁc groups, EFSA is requested by the European Commission to
perform an assessment of their safety and of the bioavailability of the nutrient from the proposed source.
This guidance describes the scientiﬁc data required to allow an evaluation of the safety of the source
within the established framework for risk assessment of food additives and novel food ingredients and the
bioavailability of the nutrient from this source. This document is arranged in ﬁve main sections: one on
technical data aimed at characterising the proposed source and at identifying potential hazards resulting
from its manufacture and stability in food; one on existing authorisations and evaluation, providing an
overview of previous assessments on the proposed source and their conclusions; one on proposed uses
and exposure assessment section, allowing an estimate of the dietary exposure to the source and the
nutrient based on the proposed uses and use levels; one on toxicological data, describing approaches
which can be used to identify (in conjunction with data on manufacture and composition) and to
characterise hazards of the source and any relevant breakdown products; the ﬁnal section on
bioavailability focuses on determining the extent to which the nutrient from the proposed source is
available for use by the body in comparison with one or more forms of the same nutrient that are already
permitted for use on the positive lists. This guidance document should replace the previous guidance
issued by the Scientiﬁc Committee for Food and published in 2001.
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Summary
The Panel on Food Additives and Nutrient Sources added to Food (ANS Panel) requested the European
Food Safety Authority (EFSA) to update existing scientiﬁc guidance on the data needed for the assessment
of sources of nutrients proposed for use in the manufacture of foods in the light of the experience accrued
over the years with this type of assessment and to reﬂect the current thinking in risk assessment.
This guidance describes the scientiﬁc data required to allow an evaluation of the safety of the
source within the established framework for risk assessment and the bioavailability of the nutrient from
this source.
The use of chemical substances as ‘sources’ of vitamins and minerals in food is regulated in the
European Union (EU) by the establishment of positive lists of substances, annexed to the relevant
sectorial legislation, i.e.:
• Directive 2002/46/EC for food supplements;
• Regulation (EC) No 1925/2006 for ‘fortiﬁed’ foods;
• Regulation (EU) No 609/2013, covering infant formula and follow-on formula (IF and FOF);
processed cereal-based food and baby food (PCBF); food for special medical purposes (FSMP);
and total diet replacement for weight control (TDR).
For the purpose of this guidance, vitamins and minerals listed in the annexes of the above
mentioned legislation are referred to as ‘nutrients’.
The positive list of Regulation (EU) No 609/2013 also contains other additional substances (i.e.
amino acids, carnitine, taurine, nucleotides, choline and inositol), which are also covered by the term
‘nutrient’ used in this guidance.
According to the Directive and the two Regulations above, the chemical substances used as sources
which may be added to food, including food supplements and foods for speciﬁc groups, should be safe
and also bioavailable, a property which is described, in the relevant legislation, as ‘available to be used
by the body’.
Whenever new substances are proposed for inclusion in any of the above positive lists of sources,
EFSA is requested by the European Commission to perform an assessment of their safety and
bioavailability.
The nutritional, physiological function or safety aspects of nutrients as such are outside the scope
of the evaluations carried out by the ANS Panel. Hence, these aspects of the nutrient are not to be
considered for this updated guidance on evaluation of sources of nutrients. In addition, the term
bioavailability as used in this guidance addresses the comparative bioavailability, namely the
bioavailability of the nutrient from the proposed source compared with the bioavailability of the
nutrient in forms that are already permitted for use on the positive lists. Hence, the term bioavailability
is conﬁned to the difference in bioavailability of the nutrient released from two different sources.
This guidance presents a common format for the organisation of the information to be presented in
order to assist the applicant in the preparation of a well-structured application to demonstrate the safety
of a proposed source and the extent to which the nutrient is available to be used by the body. Adherence
to this format will facilitate access to information and scientiﬁc data in applications which will help EFSA
to carry out its evaluation and to deliver its scientiﬁc opinion in an effective and consistent way.
For the safety assessment of the source, data requirements which should be covered in all
applications relate to the description of the source, manufacturing process (including possible residuals
or contaminants), technical speciﬁcations, proposed uses and use levels, and anticipated intake of the
source and the corresponding intake of the nutrient. Information on existing authorisation and
evaluations should also be provided.
The ﬁrst consideration to be made in assessing the safety of a proposed source of nutrients is
whether and to what extent the proposed source dissociates in the lumen of the human
gastrointestinal (GI) tract. This document provides guidance both on the type of experimental data to
be generated to establish dissociation of the source in the human GI tract lumen and on the
toxicological data required, based on the expected dissociation of the source.
The toxicological data required follows the same tiered approach applied to the evaluations of new
food additives and novel food ingredients, integrating the core areas of kinetics, genotoxicity, repeated
dose toxicity testing, and reproductive and developmental toxicity. For sources intended to be used in
infants below 16 weeks of age, the toxicity testing required shall be aligned to the latest
recommendations issued by the EFSA Scientiﬁc Committee with respect to the risk assessment of
substances present in food intended for this age group.
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In principle, for sources which extensively and readily dissociate in the GI tract into constituents
found in the diet and/or human body or have already been assessed (e.g. as food additives), existing
data will be the basis for the assessment. Tier 1 toxicity testing would be required for sources which
are absorbed unchanged from the GI tract lumen and/or when there are no existing data. The need
for additional testing of sources should be determined by the non-nutrient component generated
following dissociation. The need for higher level of testing is determined by results from Tier 1 testing
for sources which are absorbed unchanged. However there is no absorption trigger for Tier 2 testing
for sources which are absorbed intact but dissociate into components of the diet and/or the human
body by ﬁrst pass metabolism (either in the GI wall or liver before reaching the systemic circulation).
For sources which are absorbed intact and either do not dissociate before reaching the systemic
circulation or dissociate into non-nutrient components which are not natural components of the diet
and/or the human body require Tier 2 testing.
It is acknowledged that it is not always possible to determine directly whether the nutrient from the
proposed source is available to be used by the body, and therefore, a range of surrogate tests are
proposed as examples that will generate data to be used in assessing the bioavailability of the nutrient
from the proposed source. These data should allow a comparison between the behaviour of the
proposed source and one or more sources of the same nutrient, already permitted for use in foods.
Provided the dissociation between the two (or more) substances is similar, the nutrient from the
proposed source may be assumed to be as ‘available to be used by the body’ as the nutrient released
from the comparator source(s) and no further testing for bioavailability would be required. In the event
that the dissociation behaviour between the new proposed source and one of the reference sources is
not comparable, then additional testing would be required. Such tests may include more complex
dissociation test (e.g. with a simulated gastrointestinal digestion), in vitro studies (e.g. Caco-2 cell
models) and in vivo studies. Selection of the tests is to be determined on a case-by-case basis.
The guidance document was subject to consultation between the ANS Panel and the NDA
Panel and to public consultation (from 15-12-2017 to 25-2-2018) before ﬁnalisation.
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1. Introduction
This guidance document refers to the data needed for the assessment of sources of nutrients
proposed for use in the manufacture of foods. It describes the scientiﬁc data required to allow an
evaluation of the safety of the source within the established framework for risk assessment and the
bioavailability of the nutrient from this source.
1.1. Background and Terms of Reference as provided by the ANS Panel
1.1.1. Background
The use of chemical substances as ‘sources’ of vitamins and minerals in food is regulated in the
European Union (EU) by the establishment of positive lists of substances, annexed to the relevant
sectorial legislation, i.e.:
• Directive 2002/46/EC for food supplements1;
• Regulation (EC) No 1925/2006 for ‘fortiﬁed’ foods2
• Regulation (EU) No 609/2013, covering infant formula and follow-on formula (IF and FOF);
processed cereal-based food and baby food (PCBF); food for special medical purposes (FSMP);
and total diet replacement for weight control (TDR)3
For the purpose of this guidance, vitamins and minerals listed in the annexes of the above
mentioned legislation are referred to as ‘nutrients’.
The positive list of Regulation (EU) No 609/2013 also contains additional substances (i.e. amino
acids, carnitine, taurine, nucleotides, choline and inositol), which are also covered by the term
‘nutrient’ in this guidance.
According to the Directive and the two Regulations above, the chemical substances used as sources
of nutrients which may be added to food, including food supplements and foods for speciﬁc groups,
should be safe and also bioavailable, a property which is described as ‘available to be used by the body’.
Whenever new substances are proposed for inclusion in any of the above positive lists of sources,
the European Food Safety Authority (EFSA) is requested by the European Commission to perform an
assessment of their safety and bioavailability.
An opinion expressed by the Scientiﬁc Committee on Food (SCF) in 2001 provides guidance to the
applicants on the nature and extent of the information that should be submitted to establish
bioavailability of the nutrient or other ingredient and safety of the source (SCF, 2001a). In this
guidance document, reference is made to another opinion expressed by the SCF in 2001, namely the
‘Guidance on submissions for Food Additive Evaluations by the Scientiﬁc Committee on Food’, for the
toxicological data needed in support of these applications (SCF, 2001b).
Between 2005 and 2009, the AFC Panel and the ANS Panel evaluated approximately 200 dossiers of
chemical substances proposed for use as sources. These assessments were used as the scientiﬁc basis for
the European Commission to draw up positive lists of substances to be included in the relevant legislation.
In July 2012, with the adoption by the ANS Panel of the Scientiﬁc Opinion on ‘Guidance on
submission for food additive evaluations’ (EFSA ANS Panel, 2012), the latter guidance document from
the SCF has become obsolete.
At its 52nd meeting the ANS Panel indicated that the scientiﬁc principles that have been
incorporated into the 2012 guidance document for food additive evaluations should equally be applied
to the evaluation of sources of nutrients and therefore an update of the respective guidance document
was warranted.
Moreover, recently there have been cases in which the evaluation of the safety of a source has been
combined with an assessment of the substance as a novel food ingredient. The updated guidance on
sources should make provisions for the data requirement needed under these circumstances, e.g. by
making reference to the relevant food sector legislation and/or existing guidance.
1 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements OJ L 183, 12.7.2002, p. 51–57.
2 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and ovf certain other substances to foods OJ L 404, 30.12.2006, p. 26–38.
3 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 OJ L 181,
29.6.2013, p. 35–56.
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The nutritional, physiological function or safety aspects of nutrients as such are outside the scope
of the evaluations carried out by the ANS Panel and as such are not to be considered for this updated
guidance on evaluation of sources of nutrients.
Finally, the ANS Panel noted that with the adoption of Commission Regulation (EU) No 2017/2284, the
evaluation of nutrient sources and other substances with physiological effects added to foods will be
transferred to the NDA Panel on 1 July 2018. Therefore the NDA Panel was involved in the Working Group
and consulted prior to the endorsement of this Guidance for public consultation and its ﬁnalisation.
1.1.2. Terms of Reference
In accordance with Article 29(1) of Regulation (EC) No 178/20025, the European Food Safety
Authority asks its scientiﬁc Panel on Food Additives and Nutrient Sources added to Food (ANS) to
provide a scientiﬁc opinion on guidance on submissions for evaluations of sources of nutrients
proposed for use in the manufacture of food, including food supplements and foods for speciﬁc groups
of the population.
1.1.3. Interpretation of Terms of Reference
For the purpose of this guidance, and in line with the deﬁnition given in the relevant Legislation, the
Panel noted that bioavailability of a nutrient from a source is described as it being ‘available to be used by
the body’. Based on the terms of reference for individual assessments, the Panel has traditionally
interpreted this as the bioavailability of the nutrient from the source. However, considerations on
systemic availability of the source have always been taken into account in determining the toxicological
data requirements for the safety assessment of the source itself.
The evaluation of safety of nutrient sources does not include evaluation of the nutritional,
physiological function or safety of nutrient as such, and therefore, these aspects have not been
considered in this updated guidance on evaluation of sources of nutrients.
As it is difﬁcult to measure ‘availability to be used by the body’ for most nutrients, the Panel has
proposed a range of approaches that can be applied in order to evaluate bioavailability of the nutrient.
These approaches are comparative studies which take into consideration the bioavailability of the
chemical forms of the nutrient which are already on the positive lists.
Current Legislation treats the substances that are included in the positive lists in isolation. However
these substances are often incorporated into different matrices, such as formulated products (tablets,
capsules, etc.) or foods, and the particular formulation or product inﬂuences the bioavailability of the
nutrient. However, the Panel noted that the inﬂuence of other components is not part of the evaluation
of a source.
Regulation (EC) No 1925/2006 not only contains a positive list of substances that can be added to
food, but also, in its Annex III, Part C, lists those substances that are placed under Union Scrutiny as a
consequence of an assessment conducted in the context of Article 8 of the above mentioned
Regulation (i.e. substances for which the possibility of harmful effects on health is identiﬁed but
scientiﬁc uncertainty persists). In those cases, the applicable implementing rules6 allows a ﬁle to be
submitted by a food business operator or any other interested party to EFSA for a safety assessment
in line with relevant guidance documents adopted or endorsed by EFSA. This guidance however is not
speciﬁcally intended to provide advice for the preparation of such a ﬁle, despite the applicability of
certain parts of it to general safety assessments of food ingredients.
In addition, pursuant to Regulation (EU) No 609/2013, substances included in the positive list for the
foods for speciﬁc groups, should not only be safe and bioavailable but also have a nutritional or
physiological effect and be suitable for the persons for whom the food is intended. The Panel noted that
bioavailability of a nutrient from different sources currently included in the positive lists may be different
and some sources may not be suitable for the intended uses (i.e., infant formula and follow-on formula,
4 Commission Regulation (EU) 2017/228 of 9 February 2017 amending Regulation (EC) No 178/2002 of the European Parliament
and of the Council as regards the names and the areas of competence of the scientiﬁc panels of the European Food Safety
Authority. OJ L 35, 10.2.2017, p. 10–11.
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
6 Commission Implementing Regulation (EU) No 307/2012 of 11 April 2012 establishing implementing rules for the application of
Article 8 of Regulation (EC) No 1925/2006 of the European Parliament and of the Council on the addition of vitamins and
minerals and of certain other substances to foods. OJ L 102, 12.4.2012, p. 2–4.
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processed cereal-based food and baby food, food for special medical purposes and total diet
replacement for weight control). In assessing such products, there is a need for a holistic assessment
which in addition to the assessment of the safety of the source and the bioavailability of the nutrient
also takes into consideration the intended use(s). The principles for the assessment of the suitability of
the proposed sources to the persons for whom the food is intended are outside the scope of this
guidance.
1.2. General principles
This document should be read in conjunction with the latest available version of the document
‘Administrative guidance on submissions for safety evaluation of substances added for speciﬁc
nutritional purposes in the manufacture of foods’ prepared by the Food information and composition,
food waste Unit of the Health and Food Safety Directorate-General of the European Commission
(European Commission, online).
The assessment of the safety of the nutrient itself and the data required for these assessments do not
fall within the remit of this guidance. The scientiﬁc assessment will therefore deal with the safety of a
particular source and the bioavailability of a given nutrient from that source. The evaluation of the
nutrient itself, in relation to establishing dietary reference values (DRVs), is outside the scope of the
assessment. However, if the proposed uses and use levels of the source are likely to reach the tolerable
upper level (UL) for that nutrient, this will be taken into account in the safety assessment.
With respect to the safety of the source and the relevant dissociation products or products naturally
occurring in biological milieux, the principle of the assessment is not different from the safety
assessment of food additives, for which updated guidance was adopted by the ANS Panel in 2012
(EFSA ANS Panel, 2012). This introduced the principles of a tiered approach to toxicological testing to
reﬂect 3Rs principles (replacement, reduction and reﬁnement).
Recently, the European Commission has requested the assessment of the safety of sources that
would also fall under the deﬁnition of ‘novel food ingredients’ (NFI) according to the applicable
Regulation (EU) No 2015/22837. Also in this case, the guidance has been updated to make reference
to the latest available guidance issued by the EFSA Panel on Dietetic Products, Nutrition and Allergies
(EFSA NDA Panel, 2016).
Similarly, in the event of sources consisting of, containing, or produced from genetically modiﬁed
microorganisms, the guidance has also been updated in order to refer to the latest currently applicable
guidance (EFSA FEEDAP Panel, 2018).
In assessing the safety of a proposed source, a critical consideration is the behaviour or degree of
dissociation expected to occur in the gastrointestinal tract. When a source would be assumed to be
extensively dissociated in the gastrointestinal (GI) tract, the risk assessment can usually be based on
existing toxicological information of the resulting compounds. However, there might be cases where
toxicological information of resulting components is not available or not adequate for risk assessment
which would require producing new toxicological data.
In the context of this guidance, the term ‘dissociation’ intends to cover breakdown in whatever
form (e.g. but not limited to: dissociation of salts, complexes, chelates; ester hydrolysis; etc.).
Previous versions of this guidance required data on the bioavailability of the nutrient from the
source but provided limited information on the purpose of these data or of study designs best able to
generate such data. A more detailed description of various approaches that can be used for assessing
the bioavailability of the nutrient from the source is included in this guidance, but these are not
intended to be exhaustive or prescriptive. Applicants are advised to select and design the actual tests
on a case-by-case basis taking into account physicochemical data, and any other relevant information
on the compound.
The guidance is arranged in the following ﬁve main sections describing the data required for
assessment:
1) A general overview
2) Data requirements for dossiers
7 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22.
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a) The Technical data section characterises the proposed source and identiﬁes potential
hazards resulting from its manufacture (e.g. impurities, residuals), and stability in food (e.g.
degradation products).
b) The Existing authorisations and evaluation section provides an overview of previous
assessments on the proposed source and their conclusions.
c) The Proposed uses and exposure assessment section allows an estimate of the dietary
exposure to the source and the nutrient based on the proposed uses and use levels for
different EU Member States and various groups in the population.
d) The Toxicological data section describes approaches which can be used to identify (in
conjunction with data on manufacture and composition) and characterise hazards of the
source and any relevant breakdown products.
e) The Bioavailability data section seeks to determine the extent to which the nutrient from
the proposed source is ‘available for use by the body’ by comparing it with one or more
forms of the same nutrient that are on the positive lists.
With respect to the data required for hazard identiﬁcation of the proposed source, this guidance
adopts the tiered approach described in the ‘Guidance on submission for food additive evaluations’
(EFSA ANS Panel, 2012) which balances data requirements against the risk. The tiered approach
initially uses less complex tests to obtain hazard data; these are then evaluated to determine if they
are sufﬁcient for risk assessment or, if not, to plan studies at higher tiers. The intention is that in
developing their dossier, applicants will be able to more readily identify relevant data needs which will
allow adequate assessment of risks to humans from the intended use whilst strengthening the
scientiﬁc basis for the assessment. In addition, this approach takes into consideration animal welfare
by adopting animal testing strategies in line with the 3Rs (replacement, reﬁnement and reduction).
Where there is evidence that a source would dissociate in the human GI tract into well
characterised components, the toxicological assessment should be based on the existing databases for
these components and, depending on the time course of the dissociation, additional testing on the
source itself may not be necessary.
1.2.1. Sources that fall under the deﬁnition of Novel Food Ingredients (NFI)
according to Regulation (EU) No 2015/2283
As speciﬁed in Regulation (EU) No 2015/2283, vitamins, minerals and other substances used in
accordance with Directive 2002/46/EC, Regulation (EC) No 1925/2006 or Regulation (EU) No 609/2013
are considered to fall within the deﬁnition of novel food where:
• a production process not used for food production within the Union before 15 May 1997, which
gives rise to signiﬁcant changes in the composition or structure of a food, affecting its
nutritional value, metabolism or level of undesirable substances has been applied;
• they contain or consist of engineered nanomaterials.
Engineered nanomaterials are deﬁned in Regulation (EU) No 2015/2283 as any intentionally
produced material that has one or more dimensions of the order of 100 nm or less or that is
composed of discrete functional parts, either internally or at the surface, many of which have one or
more dimensions of the order of 100 nm or less, including structures, agglomerates or aggregates,
which may have a size above the order of 100 nm but retain properties that are characteristic of the
nanoscale.
Properties that are characteristic of the nanoscale include:
i) those related to the large speciﬁc surface area of the materials considered; and/or
ii) speciﬁc physico-chemical properties that are different from those of the non-nanoform of the
same material.
In the case of sources that fall under the deﬁnition of NFI, the information to be provided must be
in accordance with the latest applicable guidance (EFSA NDA Panel, 2016).
For new proposed sources that are also novel foods and which are being assessed for both uses
simultaneously, the requirements of both sets of guidance are generally applicable. If differences exist
in the requirements, application of the more stringent test is sufﬁcient to meet all requirements.
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1.2.2. Assessing the safety of a proposed new source
The ﬁrst consideration is to determine to what extent the source dissociates in the lumen of the
human GI tract based on data from the expected dissociation of the source in the human GI tract (key
elements of the design of the study and reporting as well as decision criteria are described in more
detail in Appendix D).
The outcome of the dissociation test will inform the toxicological data required for the assessment.
a) If data from the dissociation test demonstrate that the source is extensively and readily
dissociated in the GI tract, the safety assessment will be based on toxicological information on
the resulting compounds.
i) If the products of dissociation and/or natural separation that occurs in biological milieus
already have established health-based guidance values (HBGV) and/or other DRVs these
are used as the basis for risk assessment and no further toxicological data are needed. For
products covered by Commission Delegated Regulation (EU) 2016/20178, the deﬁned
minimum and maximums levels can be used;
ii) If the non-nutrient components do not have established HBGVs, toxicological data
requirements, in line with the tiered approach described in the 2012 ANS Panel Guidance
on Food Additives evaluations and the 2016 NDA Panel Guidance on Novel Foods are
needed (EFSA ANS Panel, 2012; EFSA NDA Panel, 2016);
b) If data from the dissociation test demonstrate that the source does not extensively and
readily dissociate (see Appendix D) in the lumen of the GI tract, then the source is likely to be
absorbed at least partly unchanged from the GI tract, and the tiered approach to toxicological
testing as described in the 2012 ANS Panel Guidance on Food Additives evaluations and 2016
NDA Guidance on Novel Foods would apply (EFSA ANS Panel, 2012; EFSA NDA Panel, 2016).
i) It is anticipated that Tier 1 testing on the nutrient source would generally be sufﬁcient if it can
be proven that after absorption the nutrient source is undergoing presystemic metabolism in
the intestinal wall or in the liver. Decisions on further testing should be made on a case-by-
case basis, following the 2012 ANS Panel Guidance on Food Additives evaluations.
ii) In the case where a source is absorbed unchanged and not fully metabolised in the
intestinal wall or presystemically, the 2012 ANS Panel Guidance on Food Additives
evaluations would trigger Tier 2 testing. However, for components which are naturally
present in food or the body, then the requirements for Tier 1 testing of the source would
generally be sufﬁcient.
Outcome of the safety assessment
The Panel would not normally deﬁne an acceptable daily intake (ADI) for a source, but would
rather base its conclusions on a comparison between the estimated exposure to the proposed source
and a reference point derived from the toxicological dataset provided.
However, if an ADI or a HBGV has been deﬁned for other uses of the same substance, the
Panel may consider this comparison of estimated exposure with this value is appropriate (e.g. source
already authorised as a food additive).
For sources that are not genotoxic and not carcinogenic, when using margin of exposure (MOE)
approaches, the Panel would generally consider a margin of at least 100 between a reference point
and the anticipated exposure sufﬁcient to account for the uncertainty for extrapolating between animal
species and human, and among human individuals. However, the Panel considers each MOE on a case-
by-case basis to determine whether the magnitude of the MOE between the anticipated exposure from
the proposed uses and use levels and the point of departure are sufﬁcient to conclude that there
would be no safety concern. In the consideration, the Panel also takes into account the uncertainties
identiﬁed in the database and a potential higher sensitivity of vulnerable population groups.
8 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the speciﬁc compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding. OJ L 25,
2.2.2016, p. 1–29.
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Unavoidable genotoxic and carcinogenic residuals
Substances assessed for their proposed use as sources cannot have genotoxic or genotoxic and
carcinogenic activity.
This paragraph therefore concerns exclusively unavoidable genotoxic and carcinogenic residuals or
contaminants, for which the Panel considered that it would be possible to use a MOE approach. The
Scientiﬁc Committee described that for contaminants a MOE of 10,000 or higher, if it is based on the
BMDL10 from an animal study, and taking into account overall uncertainties in the interpretation, would
be of low concern from a public health point of view and might be reasonably considered as a low
priority for risk management actions (EFSA, 2005). However, the Panel considered that for unavoidable
residuals, the MOE should be at least 10,000 and preferably as large as possible, and that this should
be reﬂected in the speciﬁcations. Whenever possible, it would be prudent to establish levels of this
type of residuals in the speciﬁcations as low as reasonably achievable. The Panel noted that for the
assessment of unavoidable genotoxic residuals, the Threshold of Toxicological Concern (TTC) approach
could be applied (EFSA Scientiﬁc Committee, 2012).
1.2.3. Assessing the bioavailability of the nutrient from the proposed source
As described previously in Section 1.1.3, it is generally difﬁcult to measure the ‘availability of a
nutrient to be used by the body’; therefore, this guidance recommends a range of surrogate tests to
generate data that could be used to assess bioavailability. For these approaches, the bioavailability of
the nutrient from the proposed source should be compared using the in vitro tests or in vivo studies in
humans described below (see Section 2.5), with the bioavailability of the same nutrient from one or
more sources already on the positive lists.
Choice of the source used as a comparator must be described and justiﬁed by the applicant and
results obtained with the novel source should be discussed in the context of what is known about the
bioavailability of the nutrient under examination, including considerations on the bioavailability of the
nutrient from the source chosen as a comparator.
A range of possible approaches are described in more detail in Section 2.5 and Appendix D.
1.2.4. Assessing the exposure to the source and resulting intake of the nutrient
The assessment of the exposure to the source is the qualitative and/or quantitative evaluation of its
likely intake by the European population. In addition to an estimation of the exposure to the source, it
is of particular relevance to estimate also the intake of the nutrient resulting from the proposed use(s)
and use level(s) of the source, also taking into account the dietary intake all sources, such as natural
occurrence in other foods.
In case of sources added to food (e.g. food fortiﬁcation), the exposure estimates of the source are
determined based on consumption data for the food in which the source is intended to be added and
by summing the contribution of each food in which the source is intended to be added. The resulting
intake of the nutrient is subsequently calculated.
A different paradigm applies to the sources used in food supplements and in food for speciﬁc groups,
since in these two cases the exposure estimates are not applicable to the whole European population but
only to those who are likely to use these products for particular nutritional purposes. In those cases, it is
anticipated that incorporation of the proposed source in food supplements and/or foods for speciﬁc
groups will be in such a way that a pre-deﬁned daily intake of the nutrient is achieved.
The estimates of human exposure to the source and the corresponding intake of the nutrient are
compared to the relevant health based guidance values, for example established tolerable upper levels
(ULs) for a nutrient.
2. Data requirements for dossiers
2.1. Technical data
A synopsis of categories applicable to substances proposed as new sources is presented in Table 1.
The data required for the characterisation of the aforesaid substances added to food are not different
from those already outlined for the evaluation of food additives (EFSA ANS Panel, 2012) and novel
food ingredients (EFSA NDA Panel, 2016), and depends on the nature and origin of the substance(s)
under assessment. Depending on the nature of the source, additional data requirements may be
described in other relevant guidance documents, as presented in Table 1.
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The chemistry and speciﬁcations of a substance (or mixture of substances), in terms of chemical
structure(s) and physicochemical properties, is critical information required for risk assessment and
subsequent risk management. The purity of a single substance needs to be deﬁned by speciﬁcations, and
adequate chemical characterisation of simple mixtures needs to be performed. It may not always be
possible to fully characterise more complex mixtures, but as much information as possible is required to
understand the extent to which variability in composition is controlled during manufacture. Information
on the manufacturing process is used in risk assessment to identify impurities, residuals, reaction
intermediates, precursors, and reagents that could have an inﬂuence in the toxicological evaluation.
Hazardous substances that might need to be controlled in the material of commerce need to be
identiﬁed and speciﬁed (e.g. genotoxic compounds, heavy metals). Information requirements for
analytical methods to detect and measure a source in food and during storage and over time, when used
in different food types, are critical. The identiﬁcation of degradation products might trigger toxicological
evaluation of one or more degradation products to characterise any additional hazards and risks. Where
laboratory test methods are used, validation criteria for the analytical techniques and/or methods should
be provided to demonstrate their sensitivity, speciﬁcity and associated uncertainty.
Table 1: Categories of sources and relevant EFSA Guidance documents outlining speciﬁc data
requirements for their characterisation
Category
Examples from past EFSA
opinions
Reference
1 Single substances, chemically
characterised; sources consisting
of, isolated from or produced from
material of inorganic mineral origin
Vanadium citrate, stannic
chloride, chromium picolinate,
copper aspartate, orotic acid
salts, inorganic mineral
constituents isolated from rocks
and utilised as inorganic or
organic salts or chelates
EFSA ANS Panel (2012), EFSA NDA
Panel (2016)
2 Mixtures of single substances,
chemically characterised
Selenium amino acid chelate;
iron(II)-humic acid/fulvic acid
chelate
EFSA ANS Panel (2012)
3 Complex mixtures not derived
from botanical sources, possibly
not fully chemically characterised
(chemical characterisation extent
depending on the proposed use
and use levels)
EFSA ANS Panel (2012)
4 Sources consisting of, isolated
from or produced from animals or
parts thereof
Blood peptonates EFSA ANS Panel (2012)
5 Sources of botanical origin Iodised ethyl esters of poppy
seed oil
EFSA Scientiﬁc Committee (2009,
2014)
6 Sources consisting of, isolated
from, or produced from cell
culture or tissue culture derived
from animals, plants, fungi or
algae
EFSA NDA Panel (2016)
7 Natural, derivatised and synthetic
polymers
EFSA ANS Panel (2012)
8 Sources containing
microorganisms or derived from
microorganisms, fungi or algae
Chromium-enriched yeast
Also concerning sources
consisting of, isolated from or
produced from GMMs
EFSA (2007b) and subsequent
updates, EFSA BIOHAZ Panel (2018),
EFSA GMO Panel (2011),
EFSA FEEDAP Panel (2018)
9 Nano-sized materials, engineered
and unintentionally produced
EFSA NDA Panel (2016), EFSA
Scientiﬁc Committee (2018)
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2.1.1. Identity of the substance
The information required with respect to the identity of a source will depend on the category to
which the substance belongs and is set out in detail in Appendix A. Where requested information is
not applicable or is not submitted on any of the points set out below, reasons and a scientiﬁc
justiﬁcation should be given.
In complex mixtures (e.g. extracts, protein hydrolysates), all constituents cannot in general be fully
chemically characterised and/or identiﬁed: a qualitative and quantitative characterisation of the main
constituents should be performed, at least via sum parameters.
The experience with previous assessments has shown that the characterisation of coordination
complexes or chelates is a relevant issue for the assessment of proposed sources, particularly for
minerals. A chemical complex may exhibit a reversible association of molecules, atoms, or ions through
weak chemical bonds; however, coordination complexes are known that are quite stable in that they
are bound together by considerably strong bonds. The characterisation of coordination complexes is
carried out on the basis of their physical, spectral and analytical data: results of elemental analysis and
spectral data of the uncomplexed ligands and their metal complexes must be found to be in good
agreement with their structures, this eventually proving the purity of all the substances. Speciﬁcally,
there is a requirement for scientiﬁc evidence that demonstrates the existence of the proposed complex
as the sole entity, with no relevant presence of residual unbound material and other impurities.
Information should also be provided on the identity and the quantity of impurities or by-products,
residues and contaminants. The type and the spectrum of potential target analytes should be
considered in the light of the sources and the production process. For example, for substances
produced via microbial fermentation, the presence of undesirable microbial metabolites, such as
mycotoxins, has to be investigated. For substances isolated via extraction, residues of the solvent(s)
used should be provided.
2.1.2. Proposed speciﬁcations
The proposed chemical and microbiological speciﬁcations of the source should be submitted in a
format modelled on recent EU or other internationally accepted speciﬁcations. An example is provided
in Appendix B.
Similar to what is required for the evaluation of new food additives (EFSA ANS Panel, 2012), in
order to ensure that speciﬁcations are representative of the actual material of commerce, the
analytical data supporting the speciﬁcations should also be obtained on several batches (preferably at
least 5) of the source that have been independently produced for a given method of a manufacture. A
rationale for the proposed speciﬁcations should be provided.
2.1.3. Manufacturing process
As is the case in the evaluation of new food additives (EFSA ANS Panel, 2012) and novel food
ingredients (EFSA NDA Panel, 2016), the information provided for nutrient sources is used in the risk
assessment to identify potential impurities, reaction intermediates, by-products or contaminants that
could present a hazard. Where hazards are identiﬁed (e.g. genotoxic compounds, heavy metals,
nanoparticles (non-engineered nanomaterials)), they might need to be controlled in the material of
commerce. The same level of detail as that required for food additives and NFI is therefore expected
also for the proposed sources, allowing conclusions to be drawn regarding the impact of the process
on the safety of the source and bio-availability of the nutrient from the source. In all cases a detailed
description of the manufacturing process should be provided covering the following: method of
manufacture including information on: (i) raw materials, starting substances, and other reagents and
solvents used; (ii) operational limits and key parameters of the production process; (iii) measures
implemented for production control and quality assurance (e.g. HACCP, GMP, ISO); (iv) a production
ﬂow-chart, including quality control checks.
• For substances from chemical syntheses: (i) factors such as reaction sequence, side reactions,
puriﬁcation steps, and preparation of the product to be commercialised, which may assist in
determining likely impurities (including nanoparticles) and their inﬂuence on the toxicological
evaluation; (ii) information on substances entering the manufacturing process, e.g. identity of
extraction solvent(s), reagents, reaction conditions (e.g. temperature, duration of reaction,
catalyst), special precautions (e.g. light, temperature), chemical or physical decontamination/
puriﬁcation methods (e.g. solvent extraction, crystallisation);
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• For substances derived from botanical sources: (i) information on the method(s) of
manufacture, including the process by which the raw material is converted into a preparation,
such as extraction or other procedure(s), and plant-to-extract ratio; (ii) information on
substances entering the manufacturing process, e.g. identity of the extraction solvent,
reagents, special precautions (light, temperature); (iii) standardisation criteria (e.g. see
European Pharmacopoeia) (EFSA Scientiﬁc Committee, 2009). For sources derived from plant,
animal or microbiological sources, the applicant should describe in detail the process by which
the raw material is converted into a preparation, e.g. extraction or other procedure(s), as well
as standardisation procedures. Information should also be provided on the handling of the
sources, for example the growth and harvesting conditions for plants and fungi (e.g. wild or
cultivated, cultivation practices including the use of pesticides, and time of harvest in relation
to both season and stage of the plant growth); the breeding, rearing, feeding and farming
conditions for farmed animals or the hunting, catching or collecting and killing of wild living
animals; the culture conditions for microbes and microalgae.
• For sources derived from plants, but especially when intended for use as an ingredient for
supplements, speciﬁc considerations and complementary information is provided in the EFSA
Guidance on safety assessment of botanicals and botanical preparations (EFSA Scientiﬁc
Committee, 2009) and its subsequent extension, the Scientiﬁc Opinion on a Qualiﬁed
Presumption of Safety (QPS) approach for the safety assessment of botanicals and botanical
preparations (EFSA Scientiﬁc Committee, 2014).
• For sources that would fall under the deﬁnition of NFI, the information reported in the EFSA
NDA Panel, 2016 guidance is to be followed.
If the applicant requests that the detailed description of the manufacturing process is treated
conﬁdentially, a non-conﬁdential description of the manufacturing process should also be provided,
alongside a justiﬁcation for the conﬁdentiality claims made.
2.1.4. Methods of analysis in food
By analogy to what is required for the evaluation of food additives (EFSA ANS Panel, 2012), a
minimum of a single laboratory validated analytical method should be provided for the determination of
the source and its degradation and reaction products in the foods to which the substance is intended to
be added. The method(s) provided should be speciﬁc and ﬁt-for-purpose. They should be applicable to
all the food categories to which the substance may be added. Method(s) should be given in full except
where the analytical methods used are well established and may be given by reference only.
2.1.5. Mode of incorporation, reaction and fate in food(s) to which the source is
added
Where the source is intended to be used in fortiﬁed foods, details on how the source is to be
incorporated into the food should be provided.
The stability of the source during storage, as produced and in food, should be described in order to
identify and characterise potential hazards which might arise from degradation products. In particular
data should be provided on:
• the chemical/physicochemical stability of the source in its preparation and under the conditions
of storage and effect of storage temperature, environment (light, oxygen, moisture, relative
humidity (water activity)) or any other factor that might inﬂuence the stability of the source
preparation.
• The chemical/physicochemical stability of the source during storage of the processed food: e.g.
effect of the nature of the food to which the substance is added, processing temperature, pH,
water activity or any other factor. The nature and reactivity of any degradation products and
nature of interaction/reaction of degradation products with food components.
The duration of the stability testing may depend on the type of the source and its proposed uses
and should cover at least the end of the shelf-life. Accelerated conditions (usually at higher
temperature) may be used as an alternative to stability testing under normal conditions. If the source
is used as an ingredient added to other foods, its stability in the processed foods should be
investigated in real foods or in relevant model systems (e.g. effect of processing temperature, pH and
other constituents in the processed foods).
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2.2. Information on existing authorisations and evaluations
Information on existing authorisations and evaluations should be provided for the source and the
nutrient. This should include details of the following:
• the body which carried out the evaluation;
• when the evaluation was undertaken;
• details of the evaluation identifying the critical studies and the reference points (e.g. no-
observed-adverse-effect-levels (NOAELs)/lowest-observed-adverse-effect levels (LOAELs) and
BMDL values) which are used to derive HBGV (e.g. ULs, ADIs) and the uncertainty factors used
in this evaluation;
• any uncertainties described.
2.3. Proposed uses and exposure assessment
Estimation of the intakes of the proposed source by the European population are needed for the
risk characterisation. Intakes should be estimated based on the proposed use levels of the source and
data on actual food consumption. Furthermore, a rationale for the target population, precautions and
restrictions of use should be provided, with cross-referencing to relevant safety data. Based on the
estimated intakes of the source, the resulting intakes of the nutrient should be calculated. Where
potential health hazards have been identiﬁed on the basis of the composition, toxicological or other
data, they should be discussed and adequately addressed in the proposed conditions of use to ensure
that the consumption of the source is safe for the target population. Information provided in this
section should be as precise and complete as possible.
2.3.1. Target population
The applicant should specify the intended target population, e.g. adults, the general population or
certain deﬁned population subgroups. Similarly, it should be clearly speciﬁed if certain subgroups of
the population are excluded from the intended uses (e.g. pregnant and lactating women, infants, etc.).
2.3.2. Proposed uses and use levels
This section should provide a justiﬁcation for the use of the proposed source (not just a general
justiﬁcation for the nutrient), accompanied by information on the types of products in which the
source is intended to be added/used. The information provided in this section will form the basis for
the exposure assessment.
Sources intended for use in food supplements (Directive 2002/46/EC)
In the case of sources that are intended for use in food supplements, the anticipated daily intake of
the source should be provided, alongside the corresponding anticipated daily intake of the nutrient:
• e.g. the source is intended to be used in food supplements at a typical/maximum intake level
of X mg source per day which corresponds to a recommended typical/maximum of Y mg of
nutrient per day.
If different use levels are anticipated for different population subgroups, these should be speciﬁed
in detail.
Sources intended for use in foods for speciﬁc groups (Regulation (EU) No 609/2013
In the case of sources that are intended for use in foods for speciﬁc subgroups of the population
(i.e. infant and follow-on formula, processed cereal-based baby food and baby food, food for special
medical purposes, total diet replacement for weight control), the anticipated daily intake of the source
should be provided, alongside the corresponding anticipated daily intake of the nutrient:
• e.g. the source is intended to be added to foods [specify food] product for speciﬁc groups
[specify subgroup] at a typical/maximum level of X mg source per kg or L (of the food), which
corresponds to a typical/maximum of Y mg of nutrient per kg or L (of the food).
The applicant should provide an indication of the proposed daily intake of the food product.
For nutrients added to foods for which regulatory limits deﬁne the maximum concentration of the
nutrient:
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• e.g. the source in intended to be added to foods [specify food] at a typical/maximum level
which corresponds to a maximum level not to exceed the regulatory limits established for
these products as deﬁned by Commission Delegated Regulation (EU) 2016/127.
Sources intended for use in foods (Regulation 1925/2006)
In the case of sources that are intended for use in foods (e.g. for fortiﬁcation purposes), the
applicant should specify in which type of products the source is intended to be incorporated, and the
quantities added to these products. If applicable, typical and maximum use levels should be indicated.
• e.g. the source is intended to be used in [specify food product] at a typical/maximum level of
[X] mg source per kg or L, corresponding to typical/maximum level of [Y] mg nutrient per kg
or L.
In order to support the calculation of the most reﬁned possible exposure estimations, each food
product or food category in which the source is intended to be used should be deﬁned at the highest
level of detail possible, using the FoodEx classiﬁcation system (used for the EFSA comprehensive
database) (EFSA, 2011).
2.3.3. Anticipated intake of the source and corresponding intake of the nutrient
On the basis of the information provided in Sections 2.3.1 and 2.3.2, estimations of anticipated
daily intakes of the source are required (per kg body weight and in absolute amounts). Estimations of
mean and high (at least 95th percentile) anticipated daily intakes of the source are needed for each
target population group (including, if relevant, vulnerable groups such as children, pregnant and
lactating women). The concurrent consumption of all food categories in which a source is proposed to
be used should be addressed in the estimations, possibly considering different consumption scenarios.
The highest estimated daily intake (i.e. at least the 95th percentile) among the population groups from
a representative database (e.g. EFSA Comprehensive European Food Consumption Database) is
recommended to be used as the starting point for the safety evaluation of the source. For the intake
assessment on the basis of ‘per kg body weight’, the EFSA guidance on default values and rounding
should be taken into account (EFSA Scientiﬁc Committee, 2012). Chronic intake estimates should be
provided by default. In case the available data from toxicological or human data raise concerns
regarding an acute effect, acute intake estimates should also be considered. The application should
document the methodological aspects of the intake assessment; in particular:
• the sources of data used (sources of food consumption data);
• the scientiﬁc principles and methods applied;
• the assumptions made and their rationale; in particular with respect to the assignment of a
food to a particular food category or with respect to the model used for the calculation of high
intake levels.
The Panel proposes a tiered approach where the ﬁrst step makes use of the summary statistics of
the EFSA Comprehensive Food consumption Database. Summary statistics of food consumption are
available on the EFSA website in the form of spreadsheets, both for chronic and acute consumption.
Detailed information on the database and guidance on its use have been published (EFSA, 2011).
Anticipated daily intakes for mean and high-percentile consumers can be calculated through the
combination of the intended use level in each food category with mean and high chronic consumption
values from the database, respectively.
The use of the EFSA Food Additive Intake Model (FAIM) tool (which is also based on summary
statistics of the EFSA Comprehensive Food Consumption Database) may serve as an appropriate
alternative for the ﬁrst exposure estimate. The FAIM tool was developed to support the calculation of
chronic exposure to food additives in the regulatory framework of food additives Regulation (EU)
1333/2008. Exposure assessment of food additives and intake assessment of sources added to food
for the general population share common principles. Thus, the FAIM tool may be used by applicants
for the intake assessment of sources incorporate to food for the general population, where the food
categories to which the source is intended to be added, reasonably match with the food categories
covered in the FAIM tool. It allows the applicant to estimate the mean and high-level exposure to the
sources for different population groups throughout several European countries by means of pre-
deﬁned exposure calculation worksheets. For the calculation of high percentiles of daily intake, the
model assumes that an individual might be a high-level consumer of one food category only and would
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be an average consumer of all the remaining food groups. Thus, the FAIM tool adds the highest of the
high-levels of intake from one food category (calculated for consumers only) to the mean intake values
for the remaining categories (calculated for the total population).
Summary statistics from the EFSA Comprehensive European Food Consumption Database (incl.
FAIM tool) provide valuable estimates of intake. In some cases, such estimates provide sufﬁcient
information, if high intake estimates are below HBGV (e.g. acceptable or tolerable daily intake). In
other cases, where more reﬁned estimates are needed, the applicant should consider more detailed
assessments, such as intake calculations based on individual data from national food consumption
surveys (Tier 2).
The applicant should consider and discuss the uncertainties related to the assessment; in particular,
sources of under- or over-estimations. To this end, the guidance from the EFSA Scientiﬁc Committee
related to uncertainties in dietary exposure assessment should be considered (EFSA, 2007a).
Once the intake has been estimated for the source, the resulting intake of the nutrient should be
calculated. An example is provided in Appendix C.
For nutrients added to foods where regulatory limits deﬁne the maximum concentration of the
nutrient, a reference to these regulatory limits can be provided as an estimated intake of the nutrient,
with an indication that the addition of the source will not exceed these regulatory maximums for any
nutrient.
2.3.4. Information on background exposure to the nutrient from food
The applicant should provide estimates of intake of the nutrient from the diet in relevant population
groups (e.g. from published literature).
To this end it should be noted that EFSA NDA Panel opinions on DRVs contain estimates of the
dietary intake of nutrients obtained from food consumption data available through the EFSA
Comprehensive Food Consumption Database (EFSA, 2011).
2.4. Toxicological data
Toxicity studies should be carried out with the source meeting the speciﬁcations proposed in
Appendix B and manufactured according to the production process described in Section 2.1.3. If the
test material used in the toxicity studies does not meet the speciﬁcations proposed in Appendix B or is
not manufactured according to the production process described in Section 2.1.3, a rationale should
be provided to justify why the results can be used to assess the safety of the source.
It is generally considered that the tiered toxicity testing approach proposed for food additives and
novel foods should be considered an appropriate approach also for new proposed sources. It
integrates the core areas of kinetics, genotoxicity, repeated dose toxicity testing (subchronic, chronic
toxicity and carcinogenicity) and reproductive and developmental toxicity (EFSA ANS Panel, 2012;
EFSA NDA Panel, 2016). Additional studies may be needed to examine speciﬁc biological processes
which may not be fully considered in the core areas for evaluation. Other studies that may be relevant
include, e.g. immunotoxicity and food intolerance, studies on neurotoxicity, endocrine activity and
mode of action.
In the case of sources, for example functional endpoints related to the purported function of the
nutrient may be considered as supportive evidence of bioavailability (see Section 2.5).
Deviations from the tiered approach applicable to food additives and novel foods and/or its non-
applicability should be reasoned with sound scientiﬁc arguments.
For sources intended to be used in infants below 16 weeks of age, the toxicity testing required shall
be aligned to the requirements set up in the EFSA Guidance on the risk assessment of substances
present in food intended for infants below 16 weeks of age (EFSA Scientiﬁc Committee, 2017).
2.4.1. Tiered approach for toxicity testing
A decision tree to decide on the approach for toxicological testing of sources is presented in
Figure 1.
If data from the dissociation tests demonstrate that the source is extensively and readily
dissociated in the GI tract lumen, the safety assessment will take into consideration existing
toxicological information on the resulting compounds.
If the non-nutrient component(s) part of the source are not constituents of the diet and/or human
body, the toxicological data requirements would be in line with the tiered approach devised for safety
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evaluations of food additives and novel foods (EFSA ANS Panel, 2012; EFSA NDA Panel, 2016). From
these data, a toxicological reference point (RP) is established from which either a HBGV could be
derived for comparison with the exposure estimate or a comparison could be performed of the
exposure estimate with the RP (margin of exposure approach).
If data from the dissociation test demonstrate that the source is not extensively and readily
dissociated in the GI tract lumen but is likely to be absorbed unchanged from the GI tract lumen, then
the tiered approach to toxicological testing (EFSA ANS Panel, 2012; EFSA NDA Panel, 2016) would
apply.
Hence, the minimum dataset to be provided for evaluation should comprise:
• Basic test battery for genotoxicity testing:
 A bacterial reverse mutation assay (OECD TG 471), and An in vitro mammalian cell micronucleus test (OECD TG 487).
• A modiﬁed 90-day toxicity test (OECD TG 408 with extended parameters from the OECD TG
407).
The Panel noted that the revised TG 408 with extended parameters from the OECD TG 407 is in
the process of being updated to add endocrine disruptor relevant endpoints.9
9 http://www.oecd.org/chemicalsafety/testing/Revision-OECD-TG408-repeated-dose-90-day-oral-toxicity-study-in-rodents.pdf
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Informaon on dissociaon
Does the source extensively and 
readily dissociate in GI tract?
Any trigger for Tier 2 toxicity 
tesng?
NO NO
NO
NO
YES YES
YES
YES
PARTIALLY
Is the non-nutrient part a 
constuent of the body/diet?
Use exisng data
Does the source undergo 1st pass 
metabolism?
Is the non-nutrient part a 
constuent of the body/diet?
PARTIALLY
Tier 2 toxicity tesng
Tier 1 toxicity tesng No addional toxicological data
YES
NO
chemical data
Figure 1: Decision tree for the toxicological testing of sources
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Tier 1 toxicity testing on the source would generally be required also in cases in which it can be
proven that after absorption the source is undergoing presystemic metabolism in the GI walls or in the
liver leading to substances that are normal constituent of the body and/or the diet.
If a source is absorbed unchanged and is not fully metabolised in the GI walls or presystemically,
the ANS Panel Guidance on Food Additives evaluations would trigger Tier 2 toxicity testing.
Hence, in addition to the tests above:
• A chronic toxicity (12 months) and carcinogenicity in a single species, generally the rat (either
two separate studies according to OECD TGs 452 and 451 or the combined study according to
OECD TG 453).
• Reproductive and developmental toxicity testing comprising a prenatal developmental toxicity
study (OECD TG 414) in the rabbit and an Extended One-Generation Reproduction Toxicity
Study (EORGTS) (OECD TG 443).
However, the need for this higher level of testing should be determined, in the case of sources, by the
non-nutrient component(s) generated. For components generated by ﬁrst pass metabolism, which are
normal constituents of either the diet or the body it is anticipated that Tier 1 testing of the source
would generally be sufﬁcient.
2.4.2. Additional studies
Decisions on further testing should be made on a case-by-case basis, following the 2012 ANS
Panel Guidance on Food Additives evaluations (EFSA ANS Panel, 2012).
2.5. Bioavailability data
Sources of a nutrient are usually incorporated into products (tablet, capsule, etc.) or foods, and the
matrix may affect the bioavailability of the nutrient. The Panel also acknowledged that there are a
number of other modulating factors (e.g. nutritional status) that may inﬂuence bioavailability in the
individual subject. In the context of this Guidance, the individual variability of bioavailability is not the
focus. The Guidance aims to consider the relative bioavailability of the nutrient from the source
compared under identical experimental conditions with the bioavailability of the nutrient in forms that
are already permitted for use, i.e. are on the positive lists.
There is wide variation in the bioavailability of different nutrients, and also between different forms
of the same nutrient. Therefore, the assessment of the bioavailability of a nutrient from its source
should be performed on a case-by-case basis. Various approaches can be used for assessing the
bioavailability of a nutrient (Figure 2).
•e.g.: simulated GI 
digeson, intesnal 
cells models  (e.g. 
Caco-2 cells models)
•e.g.: dissociaon 
•e.g.: acute and chronic 
studies, plasma 
kinecs, depleon-
repleon studies
Animal 
models
Human 
studies
Chemical 
data
In vitro 
studies
Figure 2: Illustrative approaches for assessing bioavailability of a nutrient
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The Panel did not consider that these approaches should be followed according a predeﬁned
hierarchy of the evidence, rather the choice should be made by applicants after careful consideration
and discussion of what is already known about the bioavailability of the nutrient under examination.
The testing strategy should be justiﬁed by the applicant based on elements such as the properties
of the source (e.g. water soluble or lipophilic compounds; nutrients released in the GI tract or nutrient
source absorbed intact) and the target population (particularly in the case of vulnerable population
groups).
The applicant should give a rationale for the selection of data. There are, however, speciﬁc
circumstances (e.g. when the proposed source would be the only source of the nutrient for the
intended population) under which human data in the relevant population would be considered
essential for the assessment.
Data from chemical dissociation tests may be considered sufﬁcient, and no further testing for
bioavailability required, when the nutrient from the proposed source can be assumed to be ‘available
to be used by the body’ on the basis of such tests. Alternative testing strategies include more complex
dissociation test (e.g. with a simulated intestinal digestion), in vitro absorption studies (e.g. intestinal
cells models such as Caco-2 cells models, or brush border membrane models) and in vivo studies.
Results from toxicological testing (e.g. Tier 1 toxicity testing, see Section 2.4.1), if they include
functional parameters related to the purported role of the nutrient, would not be sufﬁcient for a
quantitative assessment of bioavailability per se but can be considered as supportive evidence for
assessing bioavailability.
The sections below provide an overview of experimental studies that could be used to generate
data on bioavailability and criteria for assessing the results.
Experimental studies need to be designed on a case-by-case basis and, when relevant, may need
to provide data comparing the proposed source with one or more sources of the same nutrient from
the positive lists. In designing such studies, the applicant should provide a rationale for their design
choices, e.g. sampling times, culture conditions, and should deﬁne the criteria for assessing ‘availability
to be used by the body’. Bioavailability studies should be carried out with the source meeting the
speciﬁcations proposed in Appendix B and manufactured according to the production process
described in Section 2.1.3. If the test material used in the bioavailability study does not meet the
speciﬁcations proposed in Appendix B or is not manufactured according to the production process
described in Section 2.1.3, a rationale should be provided to justify why the results of the
bioavailability study can be used to assess the bioavailability of the nutrient from the source.
2.5.1. Test methods and models
Chemical data
The aim of this approach is to generate data which can predict the fate of the source in the human
body once it is ingested. This testing phase is, however, focussed on the initial phase of the digestive
process and the tests should therefore be conducted under conditions which could mimic the process
of human digestion, e.g. at a temperature of 37°C, using different buffers to simulate the different
environments of the GI tract (preferably pH 2, 4 and 6.8). The time course for the dissociation of the
source could be measured for a better understanding of the rate and the extent of the dissociation,
and this could also be compared to an already established source of the same nutrient.
Although dissociation tests have been performed for decades and reported in publications and
submissions, no validated, standardised methods are available which can be recommended to
investigate dissociation under GI conditions. Certain elements contained in OECD Guidelines for the
Testing of Chemicals, (Section 1 Physical–Chemical properties Test No. 111: Hydrolysis as a Function of
pH) and in the European Pharmacopoeia (9th edition, 5.17.1 Recommendations on Dissolution testing)
may be considered relevant also for the conduct of dissociation tests with a proposed source.
Sampling times should be determined on a case-by-case basis, but the rationale for this must be
provided. Replicate measurements for each of the sampling time should be performed.
In vitro studies
Several in vitro systems simulating human GI digestion are described in the literature, which can
assist in providing experimental evidence as whether, and to what extent, and over what time, the
nutrient component can be released from a source. The simulated gastrointestinal digestion was
described by Schricker et al. (1981) to investigate relative iron absorption from meals. Later, this
method has been used by other authors to investigate the release of other components of nutritional
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interest from different food matrixes (Gil-Izquierdo et al., 2002; Minekus et al., 2014). The most
detailed description of the method is provided by Versantvoort et al. (2004, online).
This method can be expanded to incorporate a further step in which the in vitro dialysability is
tested (Sandberg, 2005). The tests are also used to study interactions of meals with the nutrient.
Until now, however, there is no standardised method available (Marze, 2017).
In vitro systems with biological systems can be used to assess whether the nutrient source and/or
the nutrient is entering the cells, imitating the cells lining the small intestine (Etcheverry et al., 2012).
The Caco2-cell system is a well-established model for water soluble chemicals (Bessems et al., 2014).
Under special culture conditions Caco-2 cell monolayers are capable to express intestinal CYP
isozymes, phase-II enzymes and transporters. Details of the methods are described in the literature
(Ferruzza et al., 2012a,b; Natoli et al., 2012; Br€uck et al., 2017). Validation of the method and a
standard protocol are also described in the literature (Marino et al., 2005; Hubatsch et al., 2007).
Other systems have been proposed, e.g. brush border membrane vesicles (Moghimipour et al., 2016),
or human small intestinal epithelial cells (Takenaka et al., 2014).). The latter two systems, however,
are not validated to a similar extent and standard protocols are not available.
The Caco-2 cell-system has some advantages over other in vitro systems as it is more convenient
and has a high throughput and it is more accurate than isolated brush border membrane vesicles.
Rates of absorption can be determined as apparent permeability coefﬁcients (see for example:
Hubatsch et al., 2007).
In vitro models may assist in the evaluation of the stability of the compound in the GI tract and can
provide quantitative information which relates to the absorption of the nutrient from the source and
can measure some components of bioavailability. Reviews of the available methods, their applicability
to the investigation of nutrient bioavailability and their predictive values are available in the literature
(Etcheverry et al., 2012).
New developments to improve the in vitro system mimicking in wider array of parameters the
human gut have used stem cells and produced gastrointestinal organoids (Schweinlin et al., 2016) This
system has been used to study the interaction of the gut wall with the microbiome and also the
interaction of the gut wall with infectious agents (Hill and Spence, 2016; In et al., 2016). It is possible
that the system might also be used as a tool to investigate gastrointestinal absorption.
Animal models
Although animal models are known to have a limited capability to predict bioavailability in humans,
they can still provide useful insight for some nutrients (Garcıa and Dıaz-Castro, 2013; Musther et al.,
2014). In a comparative approach, results obtained in experimental animals can provide useful data on
the bioavailability of a new proposed source with respect to already established ones.
In the case of new toxicological data that are being generated in accordance with the tiered
approach presented in this guidance, ideally the studies could be expanded to cover also toxicokinetics
investigations.
Human studies
Human bioavailability studies have a long tradition and comparative designs can be used applying
different protocols and techniques. In a comparative design, studies in humans have the highest
predictive value, even if performed in a limited number of healthy subjects (EMA, 2010). Other study
designs can also be considered such as studies with chronic dosing and depletion/repletion studies.
In mass balance studies, the net dietary balance, often referred to as retention, of the nutrient is
determined from simultaneous measurements of intake and excretion (e.g. urinary and faecal) of a
radio- or stable isotope of the nutrient.
Measurement of the concentration–time proﬁle of the nutrient in plasma may also be used as a
basis to assess bioavailability of a nutrient following single or repeated oral administration of a new
proposed source. More details are provided in Appendix D.
For the assessment of nutrient bioavailability the selection of approach should be undertaken on a
case by case basis.
3. Concluding remarks
In compiling the data in support of the safety of a source and bioavailability of the nutrient from
the source, applicants should also seek to interpret the data and draw conclusions.
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The signiﬁcant ﬁndings of each toxicity study (both unpublished and published) should be
highlighted, together with the method for the identiﬁcation of the reference point, (BMDL values or the
NOAEL), and any other relevant information. The reasons for disregarding any ﬁndings should be
carefully explained. Where necessary, the conclusions should include an interpretation of the
importance of the ﬁndings in terms of possible mechanisms underlying any effects observed, a
discussion of whether these are relevant to humans and, if so, the possible importance of the
extrapolation of such ﬁndings to humans.
In terms of demonstrating that the nutrient is ‘available to be used by the body’ from the proposed
source, the applicant should seek to draw conclusions comparing the results obtained with the
proposed source and a reference source. The conclusions should allow determination whether the
bioavailability of the nutrient from the proposed source is equivalent, higher or lower than from a
reference source. The implications of this classiﬁcation for the safety of the source at the proposed
uses and use levels, and with respect to relevant health-based guidance values (e.g. ULs) should be
clearly stated.
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Glossary
Dietary Reference Value The complete set of reference values for nutrient intake comprising
Population Reference Intakes (PRI), Average Requirements (AR), Adequate
Intakes (AI), Lower Threshold Intakes (LTI) and Reference Intakes (RI).
DRVs are typically used as a basis for reference values in food labelling and
for establishing food-based dietary guidelines
Nutrient For the purpose of this document, the term nutrient covers the substances
listed in the ‘positive lists’ of the relevant legislation and any subsequent
update. The status as of 13/3/2017 is shown in the table below:
Nutrient
Directive
2002/46/EC(a)
Regulation (EC)
No 1925/2006(a)
Regulation (EU) No 609/2013(a)
FS FF IF PCBF FSMP TDR
Vitamins
Vitamin A ☑ ☑ ☑ ☑ ☑ ☑
Vitamin D ☑ ☑ ☑ ☑ ☑ ☑
Vitamin E ☑ ☑ ☑ ☑ ☑ ☑
Vitamin K ☑ ☑ ☑ ☑ ☑ ☑
Vitamin B1 (thiamine) ☑ ☑ ☑ ☑ ☑ ☑
Vitamin B2 (riboﬂavin) ☑ ☑ ☑ ☑ ☑ ☑
Niacin ☑ ☑ ☑ ☑ ☑ ☑
Pantothenic acid ☑ ☑ ☑ ☑ ☑ ☑
Vitamin B6 ☑ ☑ ☑ ☑ ☑ ☑
Folic acid (folate) ☑ ☑ ☑ ☑ ☑ ☑
Vitamin B12 ☑ ☑ ☑ ☑ ☑ ☑
Biotin ☑ ☑ ☑ ☑ ☑ ☑
Vitamin C ☑ ☑ ☑ ☑ ☑ ☑
Minerals
Calcium ☑ ☑ ☑ ☑ ☑ ☑
Magnesium ☑ ☑ ☑ ☑ ☑ ☑
Iron ☑ ☑ ☑ ☑ ☑ ☑
Copper ☑ ☑ ☑ ☑ ☑ ☑
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Nutrient
Directive
2002/46/EC(a)
Regulation (EC)
No 1925/2006(a)
Regulation (EU) No 609/2013(a)
FS FF IF PCBF FSMP TDR
Iodine ☑ ☑ ☑ ☑ ☑ ☑
Zinc ☑ ☑ ☑ ☑ ☑ ☑
Manganese ☑ ☑ ☑ ☑ ☑ ☑
Sodium ☑ ☑ ☑ ☑ ☑
Potassium ☑ ☑ ☑ ☑ ☑ ☑
Selenium ☑ ☑ ☑ ☑ ☑
Chromium ☑ ☑ ☑ ☑
Molybdenum ☑ ☑ ☑ ☑
Fluoride ☑ ☑ ☑ ☑
Chloride ☑ ☑
Phosphorus ☑ ☑
Boron ☑ ☑ ☑ ☑
Silicon ☑
Other substances
Amino acids ☑ ☑ ☑ ☑
Carnitine and taurine ☑ ☑ ☑ ☑
Nucleotides ☑ ☑ ☑
Choline ☑ ☑ ☑ ☑
Inositol ☑ ☑ ☑ ☑
FS: food supplements; FF: fortiﬁed foods; IF: infant formula and follow-on formula; PCBF: processed cereal-based food and baby
food; FSMP: food for special medical purposes; TDR: total diet replacement for weight control.
☑ included in the Annexes of the legislation cited above.
(a): As amended.
Source For the purpose of this guidance, the terms ‘source’ identiﬁes the
chemical substances used as sources of the nutrients listed above
Tolerable upper intake level The maximum intake of substances in food, such as nutrients or
contaminants, that can be consumed daily over a lifetime without
adverse health effects
Abbreviations
ADI acceptable daily intake
ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
AUC area under the curve
BMDL10 benchmark dose level
CI conﬁdence interval
DRVs Dietary Reference Values
EORGTS Extended One-Generation Reproduction Toxicity Study
FAIM Food Additive Intake Model
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
FOF follow-on formula
FSMP Food for special medical purposes
GI gastrointestinal
HBGV health-based guidance values
IF infant feed
LOAEL lowest-observed-adverse-effect level
MOE margin of exposure
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NFI novel food ingredients
NOAEL no-observed-adverse-effect-level
PCBF processed cereal-based food and baby food
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QPS Qualiﬁed Presumption of Safety
RP Reference point
SCF Scientiﬁc Committee on Food
TDR total diet replacement
TTC Threshold of Toxicological Concern
UL tolerable upper level
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Appendix A – Information on identity of a substance
Category 1 Single substances, chemically characterised; sources consisting of, isolated from or
produced from material of inorganic mineral origin
1.1 Chemical name (i.e. unequivocal trivial name), and chemical name according to IUPAC
nomenclature rules
1.2 CAS number, E Number (where appropriate), EC (or EINECS) number, and other identiﬁcation
numbers, as available from established scientiﬁc sources.
1.3 Synonyms, trade names, abbreviations
1.4 Molecular and structural formulae
1.5 Molecular weight (or atomic weight for elements) (g/mol, Da)
1.6 Particle size, shape and distribution, if applicable
1.7 Spectroscopic data (printout) such as IR, UV-VIS, NMR or MS spectra or other data
1.8 Description of physical and chemical properties: appearance, melting point, boiling point, speciﬁc
gravity, stereochemistry (if any)
1.9 Solubility (reference e.g. JECFA general method for solubility (JECFA, 2006)) in water and other
common solvents
1.10 Inﬂuence of pH on solubility; ionisation constant(s)
1.11 Octanol-to-water partition ratio (KOW)
1.12 Other data that the applicant considers may be useful to support the identity of the substance
Category 2 Mixtures of simple substances, chemically characterised
2.1 Chemical name, when appropriate, according to IUPAC nomenclature rules
2.2 Chemical composition: identity of the components of the mixture, as required for item 1
2.3 CAS number, E Number (where appropriate), EC (or EINECS) number, and other identiﬁcation
numbers, as available from established scientiﬁc sources
2.4 Synonyms, trade names, abbreviations
2.5 Proportion of each component in the mixture
2.6 Molecular and structural formulae of each component in the mixture
2.7 Molecular weight (or atomic weight for elements) (g/mol, Da) of each component in the mixture
2.8 Spectroscopic and chromatographic data (printout of spectra/chromatogram) which allow the
identiﬁcation of the components of the mixture
2.9 Description of physical and chemical properties: appearance, stereochemistry, of each component
(unless not applicable)
2.10 Solubility (reference e.g. JECFA general method for solubility (JECFA, 2006)) in water and other
common solvents
2.11 Particle size, shape and distribution, if applicable
2.12 Other data that the applicant considers may be useful to support the identity of the substance
Category 3 Complex mixtures not derived from botanical sources, possibly not fully chemically
characterised (chemical characterisation extent depending on the proposed use and
use levels)
3.1 Starting materials or source materials
3.2 Species, in case of animal origin
3.3 Chemical name, when appropriate, according to IUPAC nomenclature rules of each component
3.4 CAS number, E Number (where appropriate), EC (or EINECS) number, and other identiﬁcation
numbers, as available from established scientiﬁc sources of each component. A mixture should
also be identiﬁed with appropriate identiﬁcation number(s), if any available, from established
scientiﬁc sources
3.5 Synonyms, trade names, abbreviations
3.6 Chemical description, the level of principal components in so far as these are known and level of
unidentiﬁed components
3.7 Description of physical and chemical properties
3.8 Solubility (reference e.g. JECFA general method for solubility (JECFA, 2006)) in water and other
common solvents
3.9 Particle size, shape and distribution, if applicable
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3.10 Other data that the applicant considers may be useful to support the identity of the substance
Category 4 Sources consisting of, isolated from, or produced from animals and parts thereof
4.1 Scientiﬁc (Latin) name (zoological family, genus, species, subspecies, breed, if applicable)
4.2 Synonyms that may be used interchangeably with the scientiﬁc name
4.3 Common names (if a trivial or common name is used extensively, it should be linked to the
scientiﬁc name and part used)
4.4 Part used
4.5 Geographical origin (continent, country, region)
Category 5 Sources of botanical origin
In addition to information listed in 1–3 and 5
5.1 Scientiﬁc (Latin) name (botanical family, genus, species, subspecies, variety with author’s name,
chemotype, if applicable)
5.2 Synonyms (botanical name) that may be used interchangeably with the preferred scientiﬁc name
5.3 Common names (if a trivial or a common name is used extensively in the monograph, it should be
ﬁrmly linked to the scientiﬁc name and part used)
5.4 Part used (e.g. root, leaf, seed)
5.5 Geographical origin (continent, country, region)
5.6 Growth and harvesting conditions (wild or cultivated; cultivation practices, time of harvest in
relation to both season and stage of the plant growth)
Furthermore, data on the chemical composition of the plant-derived proposed source should be provided with
emphasis on the concentrations of relevant constituents of relevance; this includes the concentrations of the
following:
5.7 Compounds classiﬁed according to their chemical structure (e.g. ﬂavonoids, terpenoids, alkaloids)
5.8 Constituents being characteristic for the food additive (chemical ﬁngerprint, markers)
5.9 Constituents that provide reasons for concern due to their chemical, pharmacological or
toxicological properties
5.10 Information on maximum levels for microorganisms and possible contaminants, including heavy
metals, mycotoxins, pesticide residues, and polycyclic aromatic hydrocarbons (PAHs), should be
provided (EFSA Scientiﬁc Committee, 2009)
Category 6 Sources consisting of, isolated from, or produced from cell culture or tissue culture
derived from animals, plants, fungi or algae
6.1 Biological source (taxonomic information on family, genus, species, subspecies, variety)
6.2 Organ and tissue or part of the organism sourced
6.3 Laboratory or culture collection sourced
6.4 Information on the identity of cells
6.5 Cells or tissue substrate used as a Novel Food
6.6 Type of culture
Category 7 Natural, derivatised and synthetic polymers
7.1 Chemical name (i.e. unequivocal trivial name) and chemical name according to IUPAC
7.2 CAS number, E Number (where appropriate), EC (or EINECS) number, and other identiﬁcation
numbers, as available from established scientiﬁc sources
7.3 Synonyms, trade names, abbreviations
7.4 Chemical and structural formula
7.5 Molecular weight (or atomic weight for elements) (g/mol, Da) or number average molecular
weight and weight average molecular weight (if feasible)
7.6 Structural formulae of monomers and starting materials, other agents involved in the
polymerisation
7.7 Degree of substitution, percentages of substituted groups (where appropriate)
7.8 Description of physical and chemical properties
7.9 Solubility (reference e.g. JECFA general method for solubility (JECFA, 2006)) in water and other
common solvents
7.10 Particle size, shape and distribution, if applicable
7.11 Other data that the applicant considers may be useful to identify the mixture and its components
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Category 8 Sources containing microorganisms or derived from microorganism, fungi or algae
The following information is required for substances of microbial origin:
8.1 The microbial origin of food additives produced by fermentation or cultivation, including:
• name of the microorganism;
• taxonomic classiﬁcation of the microorganism;
• history of modiﬁcation of the production organism
8.2 Whether the microorganism fulﬁls the requirements for a Qualiﬁed Presumption of Safety (QPS)
(EFSA, 2007 and subsequent updates, e.g. EFSA BIOHAZ Panel, 2018). In such cases, no further
data on the microorganism itself are required
8.3 Information on residual levels of toxins
8.4 Information on the production process
8.5 Information on the identity of residual intermediates or microbial metabolites in the ﬁnal product
8.6 Other relevant information as recommended by applicable guidance documents (EFSA GMO Panel,
2011; EFSA FEEDAP Panel, 2018)
Category 9 Nano-sized materials, engineered and unintentionally produced
In addition to the information listed in 1–3 and 7, the information reported in Table 1 of the EFSA Guidance on
Engineered Nanomaterials (ENMs) is required (EFSA Scientiﬁc Committee et al., 2018):
9.1 Chemical composition, identity: information on chemical composition of the ENM including purity,
nature of any impurities, coatings or surface moieties, encapsulating materials, processing
chemicals, dispersing agents and/or other formulants (e.g. stabilisers)
9.2 Particle size (primary/secondary): information on primary particle size, size range, and number size
distribution (indicating batch-to-batch variation, if any). The same information needed for
secondary particles (e.g. agglomerates and aggregates), if present. Two methods to be used, one
being electron microscopy
9.3 Physical form and morphology: the information should indicate whether the ENM is present in a
particle-, tube-, rod-shape, crystal or amorphous form, and whether it is in free particulate form or
in an agglomerated/aggregated state as well as whether the preparation is in the form of a
powder, solution, suspension or dispersion
9.4 Particle and mass concentration: information on concentration in terms of particle number, and
particle mass per volume when in dispersion and per mass when as dry powder
9.5 Speciﬁc surface area: information on speciﬁc surface area of the ENM, essential for dry powders
9.6 Surface chemistry: information on ENM surface, including any chemical/biochemical modiﬁcations
that could modify the surface reactivity, or add a new functionality
9.7 Surface charge: information on zeta potential of the ENM
9.8 Redox potential: conditions under which redox potential was measured need to be documented
9.9 Solubility and partition properties: information on solubility of the ENM in relevant solvents and
their partitioning between aqueous and organic phase (e.g. as log KOW if appropriate)
9.10 pH: essential for liquid dispersions (e.g. aqueous suspensions)
9.11 Viscosity: information on viscosity of liquid dispersions
9.12 Density and pour density: information on density/porosity of unformulated ENM and pour density
(essential for granular materials)
9.13 Dustiness: information on dustiness of powder products, such as spices, creamers, and soup
powders
9.14 Chemical reactivity, catalytic activity: information on relevant chemical reactivity or catalytic
activity of the ENM and of any surface coating of the ENM
9.15 Photocatalytic activity: information on photocatalytic activity of relevant materials used in food
packaging, coatings and printing inks, and internal reactions
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Appendix B – Example of proposed speciﬁcations for sources
Name of the source
Synonyms
Deﬁnition
EINECS
Colour Index No
Chemical names
Chemical formula
Molecular/Atomic weight/Weight average molecular weight
Particle size of powder
Assay
Description
Appearance of a solution
Identiﬁcation
Spectrophotometry, spectrometry, chromatography, Infrared,
X-ray diffraction
Density/speciﬁc gravity XX (20°C) (25/25°C)
Refractive index
Speciﬁc rotation
pH XX–XX (XX% aqueous solution)
Degree of hydrolysis/decomposition/properties during burning
Precipitation reaction
Colour reaction
Melting range or point XX–XX°C
Viscosity
Solubility
Boiling point
Speciﬁc identiﬁcation tests and parameters
Congealing range
Distillation range
Drop point
Isoelectric point
Solidiﬁcation point
Sublimation point
Vapour pressure
Microscopic observation/examination
Purity
Loss on drying
Loss on ignition
Water or HCl insoluble matter
Water content
Conductivity
Acid/Hydroxyl value
Acidity/alkalinity
Oil content
Fat
Protein
Total sugars
Starch
Sodium chloride
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Ash Not more than XX% (XXX°C)
Viscosity Not less/more than XXX mPa.s
Wax
Residual Solvents Not more than XX mg/Kg
Residue on ignition
Non-volatile residue
Organic volatile impurities
Aldehydes
Unsaponiﬁable matter
Saponiﬁcation value
Ester value
Iodine value
Peroxide value/peroxides
Oxidising/reducing substances
Readily carbonisable substances
Speciﬁc parameters for impurities
Other speciﬁc parameters indicating the degree of purity
Chlorinated compounds
3-Monochloropropane-1,2-diol (3-MCPD)
Polycyclic aromatic hydrocarbons
Organic compounds other than colouring matters
Pentachlorophenol
Epoxides
Mercury Not more than XX lg/Kg
Cadmium Not more than XX lg/Kg
Arsenic Not more than XX lg/Kg
Lead Not more than XX lg/Kg
Aluminium/aluminium oxides Not more than XX lg/Kg (expressed as Al)
Copper
Nickel
Antimony
Chromium
Selenium
Fluorides
Microbiological criteria
Salmonella spp.
Escherichia coli (coliforms)
Staphylococcus aureus
Yeasts and moulds
Total bacterial count
Total plate count
Other safety or purity related microbiological criteria
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Appendix C – Examples of exposure estimates to a nutrient from a source
The following one is a theoretical example based on a source intended to be used in food (food
fortiﬁcation).
Exposure of the source from its proposed use levels (mg/kg food or L food) in the different food
categories for which it is intended can be estimated based on consumption data from the EFSA
Comprehensive European Food Consumption Database.
The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merging of
the categories ‘elderly’ and ‘very elderly’ in the EFSA guidance ‘Use of the EFSA Comprehensive
European Food Consumption Database in Exposure Assessment’ (EFSA, 2011).
The range (min–max) is reported. In brackets, the number of dietary surveys available in the
database.
Estimated
exposure
(mg/day)
Infants Toddlers Children Adolescents Adults The elderly
(12 weeks–
11 months)
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(≥ 65 years)
Exposure to source at the proposed use levels
Mean 50–400 (6) 200–3,000 (10) 10–3,000 (18) 10–5,000 (17) 10–3,000 (17) 50–2,000 (14)
High level
consumers
100-2,000 (5) 1,000–8,000 (8) 20–9,000 (18) 20–20,000 (17) 300–15,000 (16) 100–10,000 (14)
The corresponding intake of the nutrient from the proposed source can be estimated based on the
following information:
Because Source is comprised of [example: 10% (w/w)] nutrient, the corresponding estimated
exposure to nutrient (expressed as mg/day) can be calculated.
The range (min–max) is reported. In brackets, the number of dietary surveys available in the
database.
Estimated
exposure
(mg/day)
Infants Toddlers Children Adolescents Adults The elderly
(12 weeks–11
months)
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(≥ 65 years)
Corresponding nutrient intake from the proposed use of source in foods (from EFSA database)
Mean 5–40 (6) 20–300 (10) 1–300 (18) 1–500 (17) 1–300 (17) 5–200 (14)
High level
consumers
10–200 (5) 100–800 (8) 2–900 (18) 2–2,000 (17) 30–1,500 (16) 10–1,000 (14)
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Appendix D – Minimum criteria for acceptability of data and interpretation
of results from studies assessing bioavailability
General considerations
All the tests should be carried out with the material complying with the proposed speciﬁcations for
the source.
An established source of the tested nutrient (i.e. one of the substances included in the positive lists
of the relevant sectorial Legislation) should be used as a comparator. If that is the case, a justiﬁcation
should be provided for the choice of the comparator substance.
The analytical methods used must be well characterised, fully validated and documented.
Performance data have to be provided to demonstrate the quality of the method including accuracy,
precision, speciﬁcity, limit of detection, limit of quantitation, linearity and range. Within study,
validation should be performed using quality control samples in each analytical run.
Chemical tests
For interpretation of the results, the following parameters will be considered:
Expression of dissociation Quantity (% tested material) Time
Extensively and readily At least 80% Within 15 min
Extensively At least 80% Within 45 min
Readily 50–80% Within 15 min
Poorly < 50% Within 45 time
The test should be performed in replicates. The results from the dissolution tests of the two
sources should be compared. The following parameter will be considered to establish similarity
between the two dissociation proﬁles:
• If the two-sided 90th conﬁdence interval (CI) is fully contained in the range of 0.8–1.25, the test
release of the nutrient from the new sources is considered equivalent to the reference source.
• If the lower CI limit is below 0.8, the release of the nutrient from the new source is lower than
the release of the nutrient from the reference source.
• If the upper CI limit is higher than 1.25, the release of the nutrient from the new source is
higher than the release of the nutrient from the reference source.
In vitro studies
The test should be performed in replicates. The resulting apparent permeability coefﬁcients of the
two sources should be compared.
The following parameter will be considered to establish similarity between the two permeability
coefﬁcients:
• If the 90th two-sided CI is fully contained in the range of 0.8–1.25, the rate of absorption of
the nutrient from the new sources is considered equivalent to that of the reference source.
• If the lower CI limit is below 0.8, the rate of absorption of the nutrient from the new source is
lower than that of the nutrient from the reference source.
• If the upper CI limit is higher than 1.25, the rate of absorption of the nutrient from the new
source is higher than that of the nutrient from the reference source.
Animal models
No speciﬁc advice is given for animal studies.
Human studies
A study protocol is to be established beforehand. The study is to be performed respecting ethical
principles for medical research involving humans (Declaration of Helsinki in the current version (2013))
and all regulatory requirements have to be followed. All previous relevant literature should be
considered when designing the study.
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Primary endpoint:
The primary endpoint is to be selected depending upon the nutrient under assessment and study
designed accordingly.
If demonstration of equivalent bioavailability is based on the comparison of the plasma/blood
concentration–time proﬁles of the concentration of the nutrient from the source and from the
comparator, then the primary endpoint is the area under the curve (AUC 0-t) covering at least 80% of
AUC(0-∞).
Selection of subjects: In order to reduce variability, it is advisable to perform the studies in healthy
volunteers. Subjects should preferably be non-smokers and without a history of alcohol or drug abuse.
Testing conditions should be standardised for the new proposed source and the already established
source used as a comparator. Therefore, temporal variability in biological parameters should be
considered.
Study design: As a standard design the randomised, two-period, two-sequence single dose crossover
design is recommended.
It might be necessary to perform the study after introducing steady-state conditions. In this case, a
parallel study design can be an appropriate option. In this case, the treatment groups should be
comparable in all known variables important for the handling of the substance by the body (e.g. age,
body weight, sex).
Number of subjects: The number of subjects in the study should be based on an appropriate sample
size calculation.
Sampling (blood/plasma): The number of samples should be sufﬁcient to adequately describe the
concentration-time proﬁle. The sampling schedule should be of a duration long enough to provide AUC
(from time 0 to the last measured sample) covering at least 80% of AUC (from time 0 to time ∞).
For endogenous substances, the sampling schedule should allow characterisation of the
endogenous baseline proﬁle for each subject in each period. Often, a baseline is determined from two
to three samples taken before administration. In other cases, sampling at regular intervals throughout
day(s) or weeks prior to administration may be necessary in order to account for ﬂuctuations in the
endogenous baseline due to circadian rhythms.
Interpretation of the results: The following decision rule will be considered to establish similarity of
bioavailability. The assessment of similarity is based upon 90% conﬁdence intervals for the ratio of the
population geometric means (test/reference) for the parameters under consideration.
• If the two-sided 90th CI is fully contained in the range of 0.8–1.25, the test release of the
nutrient from the new sources is considered similar to the reference source.
• If the lower CI limit is below 0.8, the bioavailability of the nutrient from the new source is
lower than that of the reference source.
• If the upper CI limit is higher than 1.25, the bioavailability of the nutrient from the new source
is higher than that of the reference source.
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